The FIIs (foreign institutional investors) holding in Dr Reddy's Laboratories went up by about 1.5 per cent in the two months period ended September 30, 2001.
According to the latest share distribution schedule of the company, FIIs hold 21.45 per cent stake as on September 30, compared with 20 per cent as on July 31, 2001. The increase in FIIs holding was mainly compensated by the fall in Indian public holding from 17 per cent to 14.5 per cent in the same period.
With a view to enabling the FIIs to invest further in the shares of the company, Dr Reddy's annual general meeting held on August 17 passed a resolution enhancing the upper limit of FII holding from 30 per cent to 49 per cent.
As on September 30, non-resident Indians/ overseas corporate bodies (NRIs/OCBs) hold 4.91 per cent stake in the company, while American depository receipts (ADRs) account for 21.99 per cent of the paid-up capital of the company.
While the promoters of the company hold 26.03 per cent stake in the company, interestingly almost all these shares are still held in the physical form.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
